Welcome to the 2^nd

Asia Clinical Trials Outsourcing Congress

The importance of the Asia Pacific region as a clinical trials hub continues to increase significantly. Latest reports indicate that more than 90% of clinical trials conducted in Asia are multinational in scope with South Korea, India, Taiwan and China being the most popular in terms of trials launched by the top 20 global pharmaceutical companies.

Patient access and market access are viewed as significant reasons for conducting clinical trials in Asia, however different countries within the reason as seen as providing variable benefits. For example whilst China is seen as the leader in being able to recruit large volumes of patients at a reasonable low cost, Japan is perceived as providing the highest quality data for trials. Elsewhere approval times in South Korea and Singapore are significantly lower than most other Asia Pacific countries.

In general, global pharmaceutical companies’ headquarters still tend to lead the operations of global and multinational clinical trials remotely in all Asian countries except for Japan but this trend is changing as more pharmaceutical companies strive to establish a regional presence.

The past five years has seen more than half of the multinational pharmaceutical companies forming strategic partnerships with CROs in Asia and further partnerships have also been initiated with local CROs or through global CROs subcontracting with local CROs who are playing an increasing important role.

So what does the future hold for the Asia Pacific region and it’s role in conducting clinical trials?

The 2nd Asia Clinical Trials Outsourcing Congress will take an in depth view of the regions increasing importance and examine where this trend will lead as well as reviewing strategic and operational implications and regulatory and logistical obstacles and barriers.

Presentations, panel debates and round table discussions will include the following topics –

Benchmarking best practices to establish a solid clinical trials strategy in Asia Pacific
Its not all about cost! Analysing other key factors influencing conducting clinical trials in Asia
Establishing relationship with local CROs and their changing role in the clinical trial process
Utilising Asia Pacific as hub for multi-national clinical trials
Data collection and management challenges in Asia Pacific
Overview of new regulatory requirements in India
The rise of Korea as a centre for conducting clinical trials – clinical trial case study
Commercialisation opportunities in Asia Pacific
What progress has been made in IP protection in Asia Pacific
Assessing the strong physician-patient relationships created in different Asian countries and how these can increase enrolment and retention
Safety monitoring and risk management of clinical trials in Asia
Establishing a solid supply chain strategy for clinical trials in Asia
Country specific case study analysis